Attention COVID-19 Survivors: You beat it. Now you could help fight it.
Visit TheFightIsInUs.org now to learn more about the urgent need for you to donate your strength — donate your plasma.
Close

This website is intended for US healthcare professionals only. Prescribing Information Important Safety Information

CEPROTIN [Protein C Concentrate (Human)] is effective in treating and preventing purpura fulminans and venous thrombosis in patients with severe congenital protein C deficiency.1,2

Learn more about the prospective, multi-center, open-label study that demonstrated the efficacy and safety of protein C concentrate.2

Baby

This is not a real representation of a child with purpura fulminans. Due to the rarity and the nature of severe congenital protein C deficiency, real pictures are scarce.

This is not a real representation of a child with purpura fulminans. Due to the rarity and the nature of severe congenital protein C deficiency, real pictures are scarce.

CEPROTIN is indicated for neonates, pediatric and adult patients with severe congenital Protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans.1

Neonatal Case Study of Treatment of Purpura Fulminans Over 28 Days with CEPROTIN

Neonatal Case Study of Treatment of Purpura Fulminans Over 28 Days with CEPROTIN

+24h

rapid progression of purpura fulminans: appearance of the skin on the left thigh at 24 hours of age based on a case study3

Neonatal Case Study of Treatment of Purpura Fulminans Over 28 Days with CEPROTIN

+8D

improvement of skin changes on day of life 8 after treatment with CEPROTIN based on a case study3

Neonatal Case Study of Treatment of Purpura Fulminans Over 28 Days with CEPROTIN

+28D

Possible skin improvement that could be observed over 28 days of treatment with CEPROTIN based on a case study3

Photos courtesy of Bubl B, Gysling Hagemann K, Dallavès F, Bartenstein A, Nelle M, Neonatal Purpura Fulminans, Swiss Society of Neonatology, University Children’s Hospital of Berne, Switzerland.


Click arrow for Indication and Important Safety Information

Warnings and Precautions

Hypersensivity: CEPROTIN may contain trace amounts of mouse protein and/or heparin as a result of the manufacturing process. Allergic reactions to mouse protein and/or heparin cannot be ruled out. If symptoms of hypersensitivity/allergic reaction occur, discontinue the injection/infusion. In case of anaphylactic shock, the current medical standards for treatment are to be observed.

References:

  1. CEPROTIN [Protein C Concentrate (Human)] Prescribing information. Lexington, MA: Baxalta US Inc.

  2. Manco-Johnson MJ, et al. Efficacy and safety of protein C concentrate to treat purpura fulminans and thromboembolic events in severe congenital protein C deficiency. Thromb Haemost. 2016;116:56-68.

  3. Bubl B, Gysling Hagemann K, Dallavès F, Bartensein A, Nelle M, Neonatal Purpura Fulminans, Swiss Society of Neonatology, University Children’s Hospital of Berne, Switzerland.

     

Sign up below

The contact information collected in this form will be used for subscribing to our newsletter and updates on educational activities.

Sorry! There are some errors below that need to be fixed.

You have the right to opt out of receiving such electronic communications and/or our newsletter, at any time, by using the opt out link in the communication or by contacting us at privacyoffice@takeda.com or by calling 1-866-888-0660. For more information on how Takeda processes your personal data, please refer to our Privacy Notice

Please include @ in your email address (eg name@test.com)
*Required
Register

THANKS

Thank you for submitting your details.

You are about to leave this website
Please be advised that Takeda has no control over the content or presentation of the site your are to view. Takeda's Privacy Notice does not apply to the website you are about to visit.
Continue Cancel